Cargando…

Long-term effects of peroxisome proliferator-activated receptor ligand bezafibrate on N-terminal pro-B type natriuretic peptide in patients with advanced functional capacity impairment

BACKGROUND: The effects of pan-peroxisome proliferator-activated receptor (PPAR) ligand bezafibrate on N-terminal pro-B type natriuretic peptide (ProBNP) level in patients with coronary artery disease (CAD) is unknown. The current study aimed to investigate the long-term effects of bezafibrate on Pr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Node, Koichi, Inoue, Teruo, Boyko, Valentin, Goldberg, Ilan, Fisman, Enrique Z, Adler, Yehuda, Schwammenthal, Ehud, Matas, Zipora, Behar, Solomon, Tenenbaum, Alexander
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2645368/ https://www.ncbi.nlm.nih.gov/pubmed/19173749 http://dx.doi.org/10.1186/1475-2840-8-5

Ejemplares similares

Does the lipid-lowering peroxisome proliferator-activated receptors ligand bezafibrate prevent colon cancer in patients with coronary artery disease?
por: Tenenbaum, Alexander, et al.
Publicado: (2008)

Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons
por: Tenenbaum, Alexander, et al.
Publicado: (2005)

Increased prevalence of left ventricular hypertrophy in hypertensive women with type 2 diabetes mellitus
por: Tenenbaum, Alexander, et al.
Publicado: (2003)

Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention?
por: Tenenbaum, Alexander, et al.
Publicado: (2012)

Bezafibrate for the treatment of dyslipidemia in patients with coronary artery disease: 20-year mortality follow-up of the BIP randomized control trial
por: Arbel, Yaron, et al.
Publicado: (2016)

Update on the use of fibrates: focus on bezafibrate
por: Goldenberg, Ilan, et al.
Publicado: (2008)

Statins research unfinished saga: desirability versus feasibility
por: Fisman, Enrique Z, et al.
Publicado: (2005)

N-terminal pro-brain natriuretic peptide and associated factors in the general working population: a baseline survey of the Uranosaki cohort study
por: Tanaka, Atsushi, et al.
Publicado: (2017)

Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins
por: Tenenbaum, Alexander, et al.
Publicado: (2006)

Metabolic syndrome and type 2 diabetes mellitus: focus on peroxisome proliferator activated receptors (PPAR)
por: Tenenbaum, Alexander, et al.
Publicado: (2003)

Cessation of Bezafibrate in patients with chronic kidney disease improves renal function
por: Zingerman, Boris, et al.
Publicado: (2020)

Bezafibrate for X-Linked Adrenoleukodystrophy
por: Engelen, Marc, et al.
Publicado: (2012)

Therapy of Canine Hyperlipidemia with Bezafibrate
por: De Marco, V., et al.
Publicado: (2017)

Anti-kindling Effect of Bezafibrate, a Peroxisome Proliferator-activated Receptors Alpha Agonist, in Pentylenetetrazole Induced Kindling Seizure Model
por: Saha, Lekha, et al.
Publicado: (2014)

Metabolic effects of bezafibrate in mitochondrial disease
por: Steele, Hannah, et al.
Publicado: (2020)

So‐far overlooked HFpEF patients with normal natriuretic peptide level need more evidence
por: Tanaka, Atsushi, et al.
Publicado: (2022)

Antidiabetic Action of Bezafibrate in a Large Observational Database
por: Flory, James H., et al.
Publicado: (2009)

I-3 Treatment of CPT2 deficiency with bezafibrate
por: Laforet, P.
Publicado: (2011)

Bezafibrate prevents aging in in vitro-matured porcine oocytes
por: Kim, Ju-Yeon, et al.
Publicado: (2021)

Investigation of novel material for effective photodegradation of bezafibrate in aqueous samples
por: Regulska, Elżbieta, et al.
Publicado: (2014)

Bezafibrate Attenuates Pressure Overload-Induced Cardiac Hypertrophy and Fibrosis
por: Xu, Si-Chi, et al.
Publicado: (2017)

Efficacy of bezafibrate in two patients with mitochondrial trifunctional protein deficiency
por: Suyama, Tomonori, et al.
Publicado: (2020)

Bezafibrate Reduces Elevated Hepatic Fumarate in Insulin-Deficient Mice
por: Franko, Andras, et al.
Publicado: (2022)

Postprandial hyperglycemia as an etiological factor in vascular failure
por: Node, Koichi, et al.
Publicado: (2009)

N-Terminal Pro-B-Type Natriuretic Peptide Is a Predictor of Chronic Kidney Disease in an Asian General Population　― The Ohasama Study ―
por: Nakayama, Shingo, et al.
Publicado: (2019)

Effect of the lipid-lowering agent bezafibrate on tumour growth rate in vivo.
por: Mulligan, H. D., et al.
Publicado: (1991)

Myocardial capillary density in normal and diabetic male rats: Effect of bezafibrate
por: Khazaei, M, et al.
Publicado: (2013)

Expression Profiling Identifies Bezafibrate as Potential Therapeutic Drug for Lung Adenocarcinoma
por: Liu, Xinyan, et al.
Publicado: (2015)

Systematic review and meta-analysis: bezafibrate in patients with primary biliary cirrhosis
por: Yin, Qin, et al.
Publicado: (2015)

CORRIGENDUM: N-Terminal Pro-B-Type Natriuretic Peptide Is a Predictor of Chronic Kidney Disease in an Asian General Population　― The Ohasama Study ―
por: Nakayama, Shingo, et al.
Publicado: (2020)

Effect of canagliflozin on N-terminal pro-brain natriuretic peptide in patients with type 2 diabetes and chronic heart failure according to baseline use of glucose-lowering agents
por: Tanaka, Atsushi, et al.
Publicado: (2021)

Rosiglitazone and bezafibrate modulate gene expression in a rat model of non-alcoholic fatty liver disease - A historical prospective
por: Schmilovitz-Weiss, Hemda, et al.
Publicado: (2013)

Effects of a vildagliptin/metformin combination on markers of atherosclerosis, thrombosis, and inflammation in diabetic patients with coronary artery disease
por: Klempfner, Robert, et al.
Publicado: (2012)

Combined Bezafibrate and Medroxyprogesterone Acetate: Potential Novel Therapy for Acute Myeloid Leukaemia
por: Khanim, Farhat L., et al.
Publicado: (2009)

Systematic review and meta-analysis: bezafibrate in patients with primary biliary cirrhosis [Erratum]
Publicado: (2015)

Bezafibrate Exerts Neuroprotective Effects in a Rat Model of Sporadic Alzheimer’s Disease
por: Lin, Li-Fan, et al.
Publicado: (2022)

Utility of point-of-care testing of natriuretic peptides (brain natriuretic peptide and n-terminal pro-brain natriuretic peptide) in the emergency department
por: Nayer, Jamshed, et al.
Publicado: (2014)

Postprandial endothelial dysfunction in subjects with new-onset type 2 diabetes: an acarbose and nateglinide comparative study
por: Kato, Toru, et al.
Publicado: (2010)

Coronary calcium in patients with and without diabetes: first manifestation of acute or chronic coronary events is characterized by different calcification patterns
por: Shemesh, Joseph, et al.
Publicado: (2013)

Angioscopic Evaluation of Stabilizing Effects of Bezafibrate on Coronary Plaques in Patients With Coronary Artery Disease
por: Uchida, Yasumi, et al.
Publicado: (2000)

Cannot write session to /tmp/vufind_sessions/sess_26uvh59j8gm9gkp73s2g4oib14